To assess the association between the presence of neutrophil subsets (CD16dim/CD62Lbright and CD16bright/CD62Ldim) and physical activity, physical fitness and complications in patients with esophageal or stomach cancer during curative treatment
ID
Source
Brief title
Condition
- Miscellaneous and site unspecified neoplasms benign
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
- neutrophil subtypes (assessed via immune markers: CD16, CD11b, CD62L, CD10,
CD64, CD11b, CD169, CD14, HLA-DR)
- complications
- physical activity
- physical fitness (aerobic capacity, handgrip strength, physical functioning)
Secondary outcome
- total leukocytes and neutrophils count
- risk for malnutrition
- nutritional intake
- sleep
- perceived immune fitness
Background summary
Patients with esophageal- or stomach cancer in a curative treatment trajectory
have to withstand many immunological stresses, while a strong immune system is
important for recovery. It is advised to be physically active during and after
all stages of cancer treatment in order to better withstand the impact of
medical treatment and improve treatment outcomes. However, little is known
regarding the effects of physical activity and physical fitness on the immune
system during this treatment. A disbalance in neutrophil subsets
CD16dim/CD62Lbright and CD16bright/CD62Ldim as well as neutrophil activation
(CD11b, CD10 and CD62L expression) have been identified as potential markers
for risk of infection in other patient populations. Furthermore, disbalance in
the neutrophil subsets was associated with physiological stress induced by
physical activity in healthy adults. The potential role of these markers in
early identification of infection risk has not yet been investigated in
patients receiving cancer treatment.
Study objective
To assess the association between the presence of neutrophil subsets
(CD16dim/CD62Lbright and CD16bright/CD62Ldim) and physical activity, physical
fitness and complications in patients with esophageal or stomach cancer during
curative treatment
Study design
Observational cohort design
Study burden and risks
Participation in this study involves minimal risk, because most data will be
collected in usual care. Extra measurements include an extra withdrawal of 4 ml
blood during standard venapuncture, and measurements via a questionnaire at
several points in time.
Heidelberglaan 100
Utrecht 3584CX
NL
Heidelberglaan 100
Utrecht 3584CX
NL
Listed location countries
Age
Inclusion criteria
The participant is...
- Assigned to curative treatment for oesophageal cancer, cardia cancer or
stomach cancer, including chemoradiotherapy (CROSS) or chemotherapy (FLOT) and
surgical resection
- Above 18 years of age
- Able to understand and speak Dutch or English language
Exclusion criteria
no exclusion criteria
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL82429.041.22 |